Biogen (BIIB) Misses Q1 EPS by 6c; Revs Light
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Biogen (BIIB) Misses Q1 EPS by 6c; Revs Light
April 27, 2015 10:41 AM EDT
UBS analyst Matthew Roden reiterated a Neutral rating but raised his price target on Biogen (NASDAQ: BIIB) to $422.00 (from $350.00) following Q1 results. While they remain cautious on expected revisions to Tecfidera estimates they are positive on AD.
Roden's key takeaways from the call:
[1] Gross to net adjustments were higher this quarter for Tecfidera in part... More
April 24, 2015 3:32 PM EDT
BMO Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $511. The stock dropped over 6% after the company reported Q1 results that missed consensus. In the view of analyst Jim Birchenough, weakness is overdone and represents a buying opportunity.
"We are reaffirming... More
April 22, 2015 3:50 PM EDT
Baird analyst Christopher Raymond weighed in on Biogen (NASDAQ: BIIB) this afternoon following news hedge fund manager Kyle Bass has filed an IPR against a Tecfidera patent.
The analyst said the challenge does not come as a surprise and they predicted this in February after... More
